Glaukos (GKOS) Q4 EPS Loss Of US$2.32 Tests Bullish Profitability Narratives

Glaukos (GKOS) has just posted its FY 2025 numbers with Q4 revenue of US$143.1 million and a basic EPS loss of US$2.32, alongside a trailing twelve month revenue line of US$507.4 million and a basic EPS loss of US$3.28. Over recent quarters, the company has seen revenue move from US$96.7 million in Q3 2024 to US$105.5 million in Q4 2024 and then to US$143.1 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.39 in Q3 2024 to US$0.60 in Q4 2024 and US$2.32 in Q4 2025. For investors, the key question now is how much of the current margin pressure reflects a trade off against potential future growth.

See our full analysis for Glaukos.

With the headline figures on the table, the next step is to see how this earnings profile lines up with the main Glaukos narratives, where forecasts for growth and the path to profitability either align with the reported numbers or appear more challenging.

See what the community is saying about Glaukos

TTM loss of US$187.7 million keeps profitability in focus

• On a trailing twelve month basis, Glaukos reported US$507.4 million in revenue against a net loss of US$187.7 million and basic EPS of US$3.28 loss, so the business is still firmly loss making even as the top line sits just above the half billion mark.
• Consensus narrative points to revenue growth and a path to positive margins over time, yet the current loss profile provides a reality check:
  • Analysts are assuming revenue growth of 25.6% per year with margins moving from roughly a 21.4% loss to an 8.4% margin in about three years, while the latest twelve month figures show losses still sizeable in absolute terms.
  • That same consensus expects earnings of US$72.3 million by around 2028, which contrasts with the most recent twelve month loss of US$187.7 million and means a significant swing in profitability would need to occur from where the company is today.

Quarterly EPS swings from US$0.28 loss to US$2.32 loss

• Within FY 2025, basic EPS moved from a loss of US$0.32, US$0.34 and US$0.28 in Q1, Q2 and Q3 to a much larger loss of US$2.32 in Q4, even though quarterly revenue for those periods ranged between US$106.7 million and US$143.1 million.
• Bulls argue that new therapies and an expanding product lineup can support much stronger earnings over time, and the current pattern of losses cuts both ways for that view:
  • The bullish narrative expects margins to move from about a 21.4% loss today to a 10.7% margin and earnings to reach US$98.9 million by around 2028, yet FY 2025 quarterly net income figures still show losses between US$16.2 million and US$133.7 million.
  • At the same time, growing revenue from US$96.7 million in Q3 2024 to US$143.1 million in Q4 2025 fits with bulls’ focus on expanding treatment volumes, even if the recent EPS volatility highlights the execution risk that earnings may not track revenue one for one.

Have a look at how optimistic investors frame that path from losses to targets in the full bull case for Glaukos: 🐂 Glaukos Bull Case

Premium 13.7x P/S with DCF fair value above price

• Glaukos trades on a P/S of 13.7x, compared with 2.8x for the broader US Medical Equipment industry and 3.6x for peers, while a DCF fair value of about US$254.01 sits above the current share price of US$121.
• Bears focus on this combination of rich sales multiple and ongoing losses, and the current earnings profile feeds into those concerns:
  • The company has been unprofitable for several years and losses have grown at about 16.5% per year over the last five years, which sits uneasily against a valuation multiple that is several times higher than industry and peer averages.
  • Even under the more cautious analyst scenario that still assumes revenue growth of 21.6% per year and earnings of US$46.0 million by around 2028, the implied P/E of 128.4x to reach the allowed price target of US$134.38 remains high compared to a sector P/E of 28.6x.

If you want to see how skeptics connect these valuation and profitability gaps into a full thesis, the detailed bear case on Glaukos lays it all out: 🐻 Glaukos Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Glaukos on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of optimism and caution here feels familiar, you are not alone. Take a moment to review the numbers yourself and pressure test the narratives, then see what stands behind that optimism by checking the 2 key rewards.

See What Else Is Out There

Glaukos is still posting sizeable losses alongside a rich P/S multiple and relies heavily on optimistic long term earnings narratives to justify its current pricing.

If that mix of ongoing losses and a premium valuation makes you cautious, compare it with companies in our 53 high quality undervalued stocks that pair stronger fundamentals with more modest expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com